Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells

Molecular Oncology

Volumn 8, Issue 2, 2014, Pages 297-310

  Jiang, Hua ^a   Zhang, Wenhao ^a   Shang, Peipei ^a   Zhang, Hui ^a   Fu, Weijun ^a   Ye, Fei ^a   Zeng, Tianmei ^a   Huang, Hejing ^a   Zhang, Xueguang ^b   Sun, Wanping ^b   Man Yuen Sze, Daniel ^c   Yi, Qing ^d   Hou, Jian ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

^c HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adoptive immunotherapy; CD138 (syndecan 1); Chimeric antigen receptor; Multiple myeloma; NK cells

Indexed keywords

CD3 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; FAS LIGAND; GAMMA INTERFERON; GRANZYME B; IMMUNOGLOBULIN LAMBDA CHAIN; LENTIVIRUS VECTOR; LYMPHOCYTE ANTIGEN RECEPTOR; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SYNDECAN 1; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD138 GENE; CELL ACTIVATION; CELL PROLIFERATION; CELL STRAIN K 562; CHIMERA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY TEST; DNA MODIFICATION; FEMALE; GENE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IRRADIATION; LEUKEMIA CELL LINE; MALE; MOLECULAR RECOGNITION; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NATURAL KILLER CELL; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; SECRETION (PROCESS); SIGNAL TRANSDUCTION; ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL MODEL; CYTOTOXICITY; INTERFERON PRODUCTION; MIDDLE AGED; MULTIPLE MYELOMA CELL LINE;

ADOPTIVE IMMUNOTHERAPY; CD138 (SYNDECAN-1); CHIMERIC ANTIGEN RECEPTOR; MULTIPLE MYELOMA; NK CELLS;

ADULT; ANIMALS; ANTIBODIES, NEOPLASM; CELL LINE, TUMOR; FEMALE; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM PROTEINS; SINGLE-CHAIN ANTIBODIES; SYNDECAN-1; TRANSFECTION;

EID: 84894325649     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.12.001     Document Type: Article

References (46)

1. Alter G., Malenfant J.M., Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J.Immunol. Methods 2004, 294:15-22.
2. André P., Castriconi R., Espéli M., Anfossi N., Juarez T., Hue S., et al. Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors. Eur. J. Immunol. 2004, 34:961-971.
3. Arai S., Meagher R., Swearingen M., Myint H., Rich E., Martinson J., et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 2008, 10:625-632.
4. Bataille R., Jégo G., Robillard N., Barillé-Nion S., Harousseau J.L., Moreau P., et al. The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy. Haematologica 2006, 91:1234-1240.
5. Baumann P., Schneider L., Mandl-Weber S., Oduncu F., Schmidmaier R. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. Anticancer Drugs 2012, 23:131-138.
6. Boissel L., Betancur M., Lu W., Wels W.S., Marino T., Van Etten R.A., et al. Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens. Leuk. Lymphoma 2012, 53:958-965.
7. Boissel L., Betancur M., Wels W.S., Tuncer H., Klingemann H. Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leuk. Res. 2009, 33:1255-1259.
8. Chang Y.H., Connolly J., Shimasaki N., Mimura K., Kono K., Campana D. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res. 2013, 73:1777-1786.
9. Costello R.T., Boehrer A., Sanchez C., Mercier D., Baier C., Le Treut T., et al. Differential expression of natural killer cell activating receptors in blood versus bone marrow in patients with monoclonal gammopathy. Immunology 2013, 139:338-341.
10. De Santis D., Foley B., Witt C.S., Christiansen F.T. The detection of NK cell alloreactivity by flow cytometric CD107a assay. Methods Mol. Biol. 2012, 882:477-489.
11. Dhodapkar M.V., Abe E., Theus A., Lacy M., Langford J.K., Barlogie B., et al. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. Blood 1998, 91:2679-2688.
12. Favors S.E., Curd L.M., Gregg R.K. Use of the anti-inflammatory cytokine interleukin-11 to reverse HIV-1gp120 repression of a natural killer cell line. Cell. Immunol. 2012, 276:1-5.
13. Finton K.A., Strong R.K. Structural insights into activation of antiviral NK cell responses. Immunol. Rev. 2012, 250:239-257.
14. Frost P., Moatamed F., Hoang B., Shi Y., Gera J., Yan H., et al. Invivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood 2004, 104:4181-4187.
15. Glässner A., Eisenhardt M., Krämer B., Körner C., Coenen M., Sauerbruch T., et al. NK cells from HCV-infected patients effectively induce apoptosis of activated primary human hepatic stellate cells in a TRAIL-, FasL- and NKG2D-dependent manner. Lab. Invest. 2012, 92:967-977.
16. Hart A.J., Jagasia M.H., Kim A.S., Mosse C.A., Savani B.N., Kassim A. Minimal residual disease in myeloma: are we there yet?. Biol. Blood Marrow. Transpl. 2012, 18:1790-1799.
17. Hasenkamp J., Borgerding A., Wulf G., Uhrberg M., Jung W., Dingeldein S., et al. Resistance against natural killer cell cytotoxicity: analysis of mechanisms. Scand. J. Immunol. 2006, 64:444-449.
18. Heinz E., Rockey D.D., Montanaro J., Aistleitner K., Wagner M., Horn M. Inclusion membrane proteins of protochlamydia amoebophila UWE25 reveal a conserved mechanism for host cell interaction among the chlamydiae. J.Bacteriol. 2010, 192:5093-5102.
19. Hoover R.G., Gullickson G., Kornbluth J. Impaired NK cytolytic activity and enhanced tumor growth in NK lytic-associated molecule-deficient mice. J.Immunol. 2009, 183:6913-6921.
20. Hudspeth K., Silva-Santos B., Mavilio D. Natural cytotoxicity receptors: broader expression patterns and functions in innate and adaptive immune cells. Front. Immunol. 2013, 4:69.
21. Ikeda H., Hideshima T., Fulciniti M., Lutz R.J., Yasui H., Okawa Y., et al. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells invitro and invivo. Clin. Cancer Res. 2009, 15:4028-4037.
22. Imai C., Iwamoto S., Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005, 106:376-383.
23. Khoury J.D., Medeiros L.J., Rassidakis G.Z., McDonnell T.J., Abruzzo L.V., Lai R. Expression of MCL-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression. J.Pathol. 2003, 199:90-97.
24. Long E.O., Kim H.S., Liu D., Peterson M.E., Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu. Rev. Immunol. 2013, 31:227-258.
25. Lugini L., Cecchetti S., Huber V., Luciani F., Macchia G., Spadaro F., et al. Immune surveillance properties of human NK cell-derived exosomes. J.Immunol. 2012, 189:2833-2842.
26. Lutz R.J., Whiteman K.R. Antibody-maytansinoid conjugates for the treatment of myeloma. MAbs 2009, 1:548-551.
27. Maki G., Hayes G.M., Naji A., Tyler T., Carosella E.D., Rouas-Freiss N., et al. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G. Leukemia 2008, 22:998-1006.
28. Maruyama I.N., Rakow T.L., Maruyama H.I. cRACE: a simple method for identification of the 5' end of mRNAs. Nucleic Acid. Res. 1995, 23:3796-3797.
29. McDaniel J.M., Pinilla-Ibarz J., Epling-Burnette P.K. Molecular action of lenalidomide in lymphocytes and hematologic malignancies. Adv. Hematol. 2012, 2012:513702.
30. Morett A., Bottino C., Vitale M., Pende D., Cantoni C., Mingari M.C., et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 2001, 19:197-223.
31. Olson J.A., Zeiser R., Beilhack A., Goldman J.J., Negrin R.S. Tissue-specific homing and expansion of donor NK cells in allogeneic bone marrow transplantation. J.Immunol. 2009, 183:3219-3228.
32. Reynolds C., Ratanatharathorn V., Adams P., Braun T., Silver S., Ayash L., et al. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma. Bone. Marrow Transpl. 2001, 27:801-807.
33. Rousseau C., Ferrer L., Supiot S., Bardiès M., Davodeau F., Faivre-Chauvet A., et al. Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients. Tumour. Biol. 2012, 33:679-688.
34. Savan R., Chan T., Young H.A. Lentiviral gene transduction in human and mouse NK cell lines. Methods Mol. Biol. 2010, 612:209-221.
35. Schönberg K., Hejazi M., Uhrberg M. Protocol for the clonal analysis of NK cell effector functions by multi-parameter flow cytometry. Methods Mol. Biol. 2012, 903:381-392.
36. Shimasaki N., Campana D. Natural killer cell reprogramming with chimeric immune receptors. Methods Mol. Biol. 2013, 969:203-220.
37. Sun W.P., Wang F.M., Xie F., Wang G.Q., Sun J., Yu G.H., et al. A novel anti-human syndecan-1 (CD138) monoclonal antibody 4B3: characterization and application. Cell. Mol. Immunol. 2007, 4:209-214.
38. Swift B.E., Williams B.A., Kosaka Y., Wang X.H., Medin J.A., Viswanathan S., et al. Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model. Haematologica 2012, 97:1020-1028.
39. Tam Y.K., Maki G., Miyagawa B., Hennemann B., Tonn T., Klingemann H.G. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum. Gene Ther. 1999, 10:1359-1373.
40. Tam Y.K., Miyagawa B., Ho V.C., Klingemann H.G. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J.Hematother. 1999, 8:281-290.
41. Tassev D.V., Cheng M., Cheung N.K. Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor. Cancer Gene Ther. 2012, 19:84-100.
42. Tonn T., Becker S., Esser R., Schwabe D., Seifried E. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J.Hematother. Stem null. Res. 2001, 10:535-544.
43. Uherek C., Tonn T., Uherek B., Becker S., Schnierle B., Klingemann H.G., et al. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 2002, 100:1265-1273.
44. Vivier E., Raulet D.H., Moretta A., Caligiuri M.A., Zitvogel L., Lanier L.L., et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011, 331:44-49.
45. Wijdenes J., Dore J.M., Clement C., Vermot-Desroches C. CD138. J.Biol. Regul. Homeostatic. Agents 2002, 16:152-155.
46. Yan Y., Steinherz P., Klingemann H.G., Dennig D., Childs B.H., McGuirk J., et al. Antileukemia activity of a natural killer cell line against human leukemias. Clin. Cancer Res. 1998, 4:2859-2868.